Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy

Pediatric Infectious Disease Journal

Volumn 28, Issue 6, 2009, Pages 488-492

  Puthanakit, Thanyawee ^a,b   Kerr, Stephen J ^b,c   Ananworanich, Jintanat ^b,d   Bunupuradah, Torsak ^b   Boonrak, Pitch ^b   Sirisanthana, Virat ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b Thailand Research Collaboration   (Thailand)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d South East Asia Research Collaboration with Hawaii ^*  (Thailand)

Author keywords

Antiretroviral therapy; Cd4; NNRTI; Pediatrics; Resource limited settings

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; THAILAND; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

EID: 67649559583     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318194eea6     Document Type: Article

References (21)

1. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528.
2. Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ. 2003;327:1019.
3. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS. 2004;18: 1905-1913.
4. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;44:599-604.
5. O'Brien DP, Sauvageot D, Zachariah R, et al. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS. 2006;20:1955-1960.
6. O'Brien DP, Sauvageot D, Olson D, et al. Treatment outcomes stratified by baseline immunological status among young children receiving nonnucleo-side reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings. Clin Infect Dis. 2007;44:1245-1248.
7. Kline MW, Rugina S, Ilie M, et al. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir- containing highly active antiretroviral therapy. Pediatrics. 2007;119: e1116-e1120.
8. World Health Organization. Antiretroviral Therapy of HIV Infection in Infants and Children in Resource-Limited Settings: Towards Universal Access. Geneva, Switzerland: WHO; 2006.
9. Therapy Twgoa. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at: www.aidsinfo.nih.gov. February 28, 2008.
10. Soh CH, Oleske JM, Brady MT, et al. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet. 2003;362:2045-2051.
11. Walker AS, Doerholt K, Sharland M, et al. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS. 2004;18:1915-1924.
12. Resino S, Resino R, Micheloud D, et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis. 2006;42:862-869.
13. van Rossum AM, Scherpbier HJ, van Lochem EG, et al. Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status. AIDS. 2001;15:2267-2275.
14. Garcia F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr. 2004;36:702-713.
15. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005;41:361-372.
16. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44:441-446.
17. Nicastri E, Angeletti C, Palmisano L, et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS. 2005;19:577-583.
18. Moore AL, Mocroft A, Madge S, et al. Gender differences in virologic response to treatment in an HIV-positive population: a cohort study. J Acquir Immune Defic Syndr. 2001;26:159-163.
19. Braga P, Cardoso MR, Segurado AC. Gender differences in survival in an HIV/AIDS cohort from Sao Paulo, Brazil. AIDS Patient Care STDS. 2007;21:321-328.
20. Patel K, Hernan MA, Williams PL, et al. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis. 2008,46: 1751-1760.
21. Kaufmann GR, Bloch M, Finlayson R, et al. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS. 2002;16:359-367.